Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.61 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.58 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3564762 | 0.98 | IMPDH2 (0.59) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| Hydrochloric Acid SCHEMBL2162309 | 0.98 | IMPDH2 (0.59) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL21430054 | 0.88 | IMPDH2 (0.62) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL20262924 | 0.87 | KDM4E (0.66) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL30176801 | 0.87 | KDM4E (0.66) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL19860095 | 0.86 | IMPDH2 (0.62) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL12201798 | 0.85 | PRMT3 (0.64) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL2162755 | 0.85 | NOTUM (0.62) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| Hydrochloric Acid SCHEMBL111600 | 0.84 | PRMT3 (0.62) | IMPDH2PRMT3ROCK2ROCK1NOTUM | |
| SCHEMBL19900450 | 0.83 | IMPDH2 (0.66) | IMPDH2PRMT3ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034943-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7671205-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137364-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885PRMT3 1026/4885ROCK2 246/4885 |
| US-20070173530-A1 | 6-Aminoisoquinoline Compounds | COQ8A, PGC, AGK | IMPDH2 2131/4885PRMT3 1026/4885ROCK2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.